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Abstract
Background: Cancer biomarkers are sought to support cancer diagnosis, predict cancer patient response to treatment and
survival. Identifying reliable biomarkers for predicting cancer treatment response needs understanding of all aspects of
cancer cell death and survival. Galectin-3 and Beclin1 are involved in two coordinated pathways of programmed cell death,
apoptosis and autophagy and are linked to necroptosis/necrosis. The aim of the study was to quantify galectin-3 and
Beclin1 mRNA in human cancer tissue cDNA panels and determine their utility as biomarkers of cancer cell survival.
Methods and Results: A panel of 96 cDNAs from eight (8) different normal and cancer tissue types were used for
quantitative real-time polymerase chain reaction (qRT-PCR) using ABI7900HT. Miner2.0, a web-based 4- and 3- parameter
logistic regression software was used to derive individual well polymerase chain reaction efficiencies (E) and cycle threshold
(Ct) values. Miner software derived formula was used to calculate mRNA levels and then fold changes. The ratios of cancer to
normal tissue levels of galectin-3 and Beclin1 were calculated (using the mean for each tissue type). Relative mRNA
expressions for galectin-3 were higher than for Beclin1 in all tissue (normal and cancer) types. In cancer tissues, breast,
kidney, thyroid and prostate had the highest galectin-3 mRNA levels compared to normal tissues. High levels of Beclin1
mRNA levels were in liver and prostate cancers when compared to normal tissues. Breast, kidney and thyroid cancers had
high galectin-3 levels and low Beclin1 levels.
Conclusion: Galectin-3 expression patterns in normal and cancer tissues support its reported roles in human cancer. Beclin1
expression pattern supports its roles in cancer cell survival and in treatment response. qRT-PCR analysis method used may
enable high throughput studies to generate molecular biomarker sets for diagnosis and predicting cancer treatment
response.
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Introduction
Cancer biomarkers are sought to help in definitive diagnosis,
treatment responses, and predicting survival of cancer patients
[1,2]. In order to predict cancer treatment response, reliable
markers of cancer cell death and survival pathways and how they
are affected by cancer treatment modalities are needed. Available
methods to identify such markers include genomics, proteomics
and tissue based immunohistochemical staining [3]. Quantitation
of cancer biomarker transcripts using real-time quantitative
polymerase chain reaction (qRT-PCR) of large samples may help
in the search for clinically useful cancer biomarkers that can be
integrated into clinical trial design [4].
The desired end-point in the treatment of human cancers is to
produce total cancer cell death [5,6]. Cancer cell death can
proceed via apotosis (type I), necrosis or autophagy (type II) [7,8].
Necroptosis (necrosis) is a programmed cell death pathway that
requires the formation of necrosome, has a natural inhibitor
(necrostatin1), and requires the functioning complex of RIP1 and
RIP3 (serine/threonine kinase receptor interacting proteins 1/3)
[9,10,11,12]; necroptosis can be induced by other pathways such
as toll-like receptors (TLR), Jun kinases, CD40, SPP1 and
glutathione metabolism [13]. Necroptosis and apoptosis have
some common regulators. RIP3 can move cells from apoptosis to
necroptosis [14]. Induction of autophagy can complement drug-
induced cancer cell death [15]. There is growing consensus that all
three programmed cell-death pathways are interconnected
[16,17]. Furthermore, one principal feature of most cancers is to
resist cell death [18]. Many factors and signaling pathways lead to
cancer cell death [8]. Inhibiting autophagy may promote necrotic
cell death [19], apoptosis [20], and apoptosis can switch to
autophagy [21] and vice-versa [22].
Galectin-3, a member of the galectin family (galectins 1–15), has
both anti- and pro-apoptotic effects, expressed in the nucleus and
cytoplasm [23,24], affects Ras-signaling in cancers[25] and
nuclear localization may induce resistance to treatment [26,27].
Galectin-3 is present in many normal tissues and cell types [28]
including endothelial cells [29]. Galectin-3 expression has been
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many human cancer types such as breast and thyroid cancers
[24,30,31]. Galectin-3 regulates other signaling pathways [32].
Galectin-3 signaling has not been linked to autophagy but has
BH1 domain of Bcl-2 and interacts with Bcl-2 [33,34] and thus
could interact with the autophagy pathway.
Beclin1 (also known as Atg6) is an autophagy related protein
and haploinsufficient tumor suppressor gene and oncogene [35]
and is highly expressed in many human cancers. Beclin1 over-
expression may promote cancer cell survival [5]. Beclin1 is deleted
in some cancers [36]. Beclin1 is a class III phosphatidylinositol 3-
kinase [37,38]. Autophagy genes are regulated by cell-cycle genes
(E2-F1) [39], oncogenes [40,41,42] and inositol triphosphate
receptor [43].
Apoptosis and autophagy are activated by similar signals such as
stress, drugs, radiation and are regulated by similar pathways such
as Bcl-2, Bax, phosphatase and tensin homologue deleted in
chromosome 10 (PTEN), mammalian target of rapamycin
(mTOR), Akt, and p53 [5,8,16,20,44,45,46,47,48]. This suggests
that expressions of galectin-3 may regulate or be related to
autophagy in cancers and act as additional mode of influencing
cancer progression.
The aim of the study was to determine expression levels of
galectin-3 and Beclin1 in both normal and cancer tissues and
correlate expression patterns in cancer types.
The present study used qRT-PCR to determine mRNA levels of
galectin-3 and Beclin1 in human cancers. Galectin-3 mRNA levels
were higher than Beclin1 in all tissue types and over-and under-
expression of both galectin-3 and Beclin1 were seen in normal and
cancer tissues. The findings support the known effects of galectin-3
on the behavior and progression of certain human cancer types.
Beclin1 expression levels suggested contribution to cancer behavior
and proposed role in cancer treatment response. The method of
qRT-PCR data analysis will be of help in large-scale studies to
determine useful cancer cell death biomarkers.
Materials and Methods
TissueScan cDNA Panel for Quantitative Real –Time
Polymerase Chain Reaction (qRT-PCR)
Origene Oncology TissueScan cDNA panel of 96 samples of
human normal (3) and cancer tissues (9)(breast, colon, kidney, liver,
ovary, prostate, lung and thyroid) was obtained from Origene Inc
(CSRT101; 2–96well pack). Breast tissues were from females only,
ages 42–63years. Colon samples were from males and females, ages
42–91years. Kidneysamples were frommales and females, ages 32–
57 years. Lung samples were from males and females, ages 49–79
years. Liver samples were from males and females, ages 21–86
years. Thyroid samples were from females and males, ages 15–74
years. Ovary samples were from females only, ages 31–80years.
Prostate samples were males only, ages 53–71years.
Primers for QRT-PCR
The primers for Galectin-3 (LGALS3 chromosome 14q21–q22,
NCBI GenBank ID NM-002306), Beclin1 (BECN1, Chromo-
some17q21: NCBI GenBank ID 003766) and b-Actin (ACTB;
NCBI GenBank ID 001101) are in Table 1 including amplicon
size and lengths of primers. The primers were obtained from
PrimerBank [49]. The purified oligonucletides were purchased
from IDT (Integrated DNA Technologies Inc).
Quantitative RT-PCR (qRT-PCR)
Quantitative real-time polymerase chain reactions (qRT-PCRs)
were carried out at the Integrated Biomolecular Design Labora-
tories (IBD) in the Department of Biochemistry, Faculty of
Medicine and Dentistry University of Alberta using Applied
Biosystems 7900HT Fast Real-Time PCR system (Applied
Biosystems Inc CA, USA). The reaction mix contained 5 mLo f
sample mixed with 15microL of PCR cocktail (primer 2,8 mM and
Jump2X ( dNTP 160 mL, ROX 400 mL, SYBER GREEN 1/00
DMSO 50 mL, Jumpstart Taq 240 mL Total 10 mL) at a ratio of
1:2).Each well was run in duplicate for test primer and reference
(b-actin) and a duplicate sample set was run for each primer of
interest. The reaction for each well was carried out as follows:
95uC for 3 minutes, followed by 95uC for 15 seconds, 55uC for
15 seconds, 72uC for 1 minute X 40 cycles, then followed by 95uC
for 15 seconds, then 60uC for 15 seconds and finally 95uC for
15 seconds. The ABI7900HT software (SD 2.0) was used to obtain
raw fluorescence data (Rn and DRn) for analysis.
qRT-PCR Data Analysis
All raw fluorescence data (Rn) for each well (in duplicate) were
uploaded to the Miner website (www.ewindup.info/miner/ver-
son2) for analysis using 4- and 3-parameter logistic regression
model to calculate efficiencies (E) and cycle threshold (Ct) values
derived from the second derivative maximum of the model [50];
the kinetic model does not require use of standard curve, defines S
shaped curve for each PCR, identifies the exponential phase(EP) of
the PCR reaction, estimates efficiency (E) using iterative non-
linear regression followed by weighted average to fit the appro-
priate curve of the raw data and Ct derived from second derivative
maximum. Miner software provided the results for each well and
the average Ct and Efficiency for each well. Samples were in
duplicate and the mean/average was used in calculations of
efficiency (E) and Ct. Similar methods have been used by others
such as the sigmoidal curve fitting model [51,52,53] and linear
regression model [54]. Many aspects of MIQE guidelines were
taken into consideration for methods and analysis [55].
Statistical Analysis
The statistical software package R (www.r-project.org) was used
to calculate relative concentrations (fold change) of mRNA levels
of galectin-3 and Beclin1 in the samples using the Miner formula
Table 1. Primers for Galectin-3, Beclin1 and b-Actin used for qRT-PCR.




LGALS3 amplicon size=161, location 59-39=13-33, 39-59=173-155. BECN1 amplicon size=188, location 59-39=104-123, 39-59=291-271. ACTB amplicon size=250,
location 59-39=393-413, 39-59=642-622.
doi:10.1371/journal.pone.0026150.t001
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statistical analysis.
Results
Galectin3 mRNA Up-regulation in Human Cancer Tissues
Overall galectin-3 mRNA levels in all 96 samples is shown in
Fig. 1a. Minimum value was 1.2e-03 and maximum value was
937e-02 (mean=67.6047e-02+/2130.3e-02). Relative mRNA
levels of galectin-3 in normal tissues are in Fig. 1b and for
cancer tissues in Fig. 1c. The highest level of galectin-3 in normal
tissues was in colonic mucosa. Normal and cancer tissues from the
liver and lung had the lowest expressions of galectin-3. High
galectin-3 expressing cancer tissues were breast, prostate, kidney
and thyroid when compared to normal tissues (Tables 2,and 3).
Beclin1/Atg6 mRNA in Human Normal and Cancer
Tissues
Relative mRNA levels for Beclin1, in all 96 tissue types were
lower compared to galectin-3 (Fig. 2a). Minimum value was
1.27e-05 and maximum value was 5.15e-01 (mean=3.18056e-
02+/26.4003e-02). The distribution of Beclin1 mRNA in normal
tissues is presented in Fig. 2b and for cancer tissue types is shown
in Fig. 2c and Tables 4 and 5. Colon, prostate, and liver cancer
tissues had high relative mRNA values.
Imbalance of Galectin-3 and Beclin1/Atg6 Expression In
Normal and Cancer tissues
Expression levels of mRNAs for galectin-3 and Beclin1 in all 96
tissues are shown in Fig. 3. Wilcoxon Signed-Rank tests for the
differences between galectin-3 and Beclin1 showed p-value of
2.22045e-1(two-tailed). In breast cancer tissues, galectin-3 but not
Beclin1 was highly expressed in cancer compared to normal tissue.
In colonic cancer tissues, Beclin1 was higher in cancer compared
to normal, while galectin-3 was lower compared to normal tissues.
Beclin1 level was higher in cancer than normal liver tissues while
galectin-3 was low though higher in cancer than normal tissues.
Kidney and thyroid cancer tissues had high galectin-3 but lower
Beclin1 in cancer compared to normal. In the ovaries, both
galectin-3 and Beclin1 levels were lower in cancers compared to
normal ovarian tissues. Lung tissues had lower galectin-3 and
higher Beclin1 in cancer compared to normal. Prostate cancer
Figure 1. Galectin-3 mRNA levels in Human Normal and Cancer Tissues. (A) Box-plot of the overall Galectin-3 expression in all tissue types.
(B) Box plots of galectin-3 distribution of relative mRNA levels in normal Tissues (Na=normal breast, Nb=Normal colon, Nc=Normal kidney,
Nd=Normal liver, Ne=Normal lung, Nf=Normal ovary, Ng=Normal Prostate, Nh=Normal thyroid). (C) Box plots of relative mRNA Levels of galectin3
in cancers tissues. BrCa=Breast cancer, Col_Ca=colon cancer, Ca_Kid=Kidney cancer, Ca_Liv=liver cancer, Ca_Lun=lung cancer, Ca_Ova=ovarian
cancer, Ca_Pros=Prostate cancer, Ca_Thyr=thyroid cancer (see Table 2a, and b for values for each group).
doi:10.1371/journal.pone.0026150.g001
Table 2. Summary of normalized galectin-3 mRNA levels in





Normal Breast 21.476e-02 Breast Cancer 61.299e-02
Normal Colon 34.615e-02 Colon Cancer 27.471e-02
Normal Kidney 77.705e-02 Kidney Cancer 156.67e-02
Normal Liver 18.151e-02 Liver Cancer 44.6160e-02
Normal Lung 52.249e-02 Lung Cancer 11.1460e-02
Normal Ovary 66.595e-02 Ovarian Cancer 24.254e-02
Normal Prostate 21.634e-02 Prostate Cancer 116.12e-02
Normal Thyroid 30.185e-02 Thyroid Cancer 68.058e-02
doi:10.1371/journal.pone.0026150.t002
Table 3. Summary of minimum, median, and maximum
values of relative galectin-3 mRNA levels in normal and cancer
tissues to complement Figures 1a and b.
Tissue Type Minimum Median Maximum
Normal Breast 0.01506 0.0764 0.553
Breast cancer 0.102 0.50 1.569
Normal colon 0.318 0.696 9.3714
Colon cancer 0.0337 0.1524 0.9418
Normal kidney 0.1347 0.9965 1.2
Kidney cancer 0.0118 0.6298 7.7939
Normal liver 0.1363 0.20122 0.20705
Liver cancer 0.0012 0.17409 2.1651
Normal lung 0.2548 0.2929 1.0197
Lung cancer 0.0052 0.0588 0.4839
Normal ovary 0.3582 0.7185 0.92118
Ovary cancer 0.01455 0.10754 1.0375
Normal prostate 0.09868 0.10115 0.44919
Prostate cancer 0.07828 1.0284 2.6502
Normal thyroid 0.0213 0.40815 0.47609
Thyroid cancer 0.11338 0.54332 1.8976
doi:10.1371/journal.pone.0026150.t003
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levels (Tables 2, 3, 4 and 5; Figure 4).
Discussion
This study was to quantify transcript levels of two cell death
markers in human normal and cancer tissues, compare levels
between normal and cancer tissues, and compare and correlate
levels in the different cancer types. The study found elevated levels
of galectin-3 mRNA and relatively low levels of Beclin1 mRNA.
The distribution of galectin-3 mRNA levels in normal and cancer
tissues are higher than for Beclin1 (Tables 2, 3, 4, and 5); there is
no indication that this implies that galectin-3’s function in
apoptosis interferes with Beclin1’s autophagy functions. That
interaction, if identified, could impact cancer treatment response.
Both galectin-3 and Beclin1 can transport to nuclei [56,57], reach
the Golgi organelle [58] and interact with Bcl-2 [33] and are
inhibited by Bcl-2 [44,59]. Beclin1 is also a therapeutic target [60]
as autophagy can increase resistance to irradiation; inhibition of
Beclin1 leads to increased sensitivity to irradiation [19].
Galectin-3 Role in Human in Cancer
Recent observations in a cancer xenograft model indicates that
inhibition of galectin-3, using synthetic lactulosyl-1-leucine
combined with taxol, reduced lung metastases and increased
metastases-free animals [61]; a finding that points to increasing
relevance of galectin-3 activities in human cancer. Another study
used small molecule inhibition of galectin-3 in thyroid cancer cell
lines and showed that inhibition induces apoptosis of the cancer
cells and sensitivity to doxorubicin [62]. Cancer stroma angio-
genesis may be promoted through matrix metalloproteinase
cleavage of galectin-3 N-terminus [63] in both in-vitro angiogen-
esis models and human cancer tissues. Furthermore, use of
galectin-3 inhibitors in-vitro and gal3 (2/2) animals indicate that
galectin-3 binds intergrin a5 b3 and induces angiogenesis via
vascular endothelial growth factor (VEGF) and b-fibroblast growth
factor (bFGF) [64]. In the cancers with elevated galectin-3 and
Beclin1 (liver and prostate cancers), targeting both may be of
benefit.
In the present study, galectin-3 mRNA levels were highest in
breast, lung, kidney, and thyroid cancers when compared to
normal tissues. High expressions of galectin-3 in some human
cancers indicate progression and metastatic activity of cancer, i.e
breast [65,66], kidney [67], and thyroid [68]. Galectin-3 is a
Figure 2. Beclin1/Atg6 relative mRNA levels in Human Normal and Cancer Tissues. (A). Box plot of the overall expression in all tissue types.
(B) Box plots of Beclin1 distribution of mRNA levels in normal tissues (Na=normal breast, Nb=Normal colon, Nc=Normal kidney, Nd=Normal liver,
Ne=Normal lung, Nf=Normal ovary, Ng=Normal Prostate, Nh=Normal thyroid). (C) Box-whisker plots of the relative Beclin1 mRNA levels in cancer
tissues. BrCa=Breast cancer, Col_Ca=colon cancer, Ca_Kid=Kidney cancer, Ca_Liv=liver cancer, Ca_Lun=lung cancer, Ca_Ova=ovarian cancer,
Ca_Pros=Prostate cancer, Ca_Thyr=thyroid cancer (see Table 3a and b for values).
doi:10.1371/journal.pone.0026150.g002
Table 4. Beclin1/Atg6 relative mRNA Levels in Normal and
Cancer Tissues.
Normal Tissue Type Mean Cancer Tissues Mean
Normal Breast 3.4437e-02 Breast Cancer 3.598e-02
Normal Colon .301320e-02 Colon Cancer .871590e-02
Normal Kidney 10.093e-02 Kidney Cancer 3.1876e-02
Normal Liver 1.77110e-02 Liver Cancer 6.1218e-02
Normal Lung .254410e-02 Lung Cancer .536290e-02
Normal Ovary .242314e-02 Ovary Cancer .1731e-02
Normal Prostate 4.7847e-02 Prostate Cancer 10.5990e-02
Normal Thyroid 1.68790e-02 Thyroid Cancer 1.30417e-02
doi:10.1371/journal.pone.0026150.t004
Table 5. Summary of minimum, median, and maximum
values of Beclin1 mRNA levels in normal and cancer tissues to
complement Figs. 2a and b.
Tissue Type Minimum Median Maximum
Normal Breast 0.0048 0.00734 0.09116
Breast cancer 0.00241 0.02845 0.08946
Normal colon 0.00102 0.002030 0.005988
Colon cancer 0.0022988 0.00666 0.0169
Normal kidney 0.06459 0.10863 0.12958
Kidney cancer 0.00570 0.011725 0.14817
Normal liver 0.00344 0.0185558 0.03113
Liver cancer 0.011579 0.038995 0.22463
Normal lung 0.0013938 0.0015910 0.004647
Lung cancer 0.0011614 0.002225 0.02738
Normal ovary 0.803e-05 0.000404 0.006816
Ovary cancer 0.2665e-05 0.0018499 0.0037392
Normal prostate 0.018351 0.058766 0.066426
Prostate cancer 0.005257 0.051456 0.51532
Normal thyroid 0.004472 0.014862 0.031303
Thyroid cancer 0.1993e-05 0.0019467 0.04676
doi:10.1371/journal.pone.0026150.t005
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expressed in tumor vascular endothelial cells and could function
in the feed-back of stroma and cancer cells [70]. Galectin-3 has
effects on K-ras signaling in breast cancer cells [25] and its nuclear
translocation increases resistance to chemotherapy [71]. Galectin-
3 promotes metastasis in experimental breast cancer metastasis
models [72]. Galectin-3 is elevated in thyroid cancers with
mutated p53 especially poorly differentiated and anaplastic
subtypes [73]. High levels of galectin-3 in these subtypes have
spurred the use of galectin-3 in imaging of these cancers [68] and
as therapeutic target [31]. As was found in this study, galectin-3 is
expressed in normal thyroid [74] and the higher levels in thyroid
cancers, as seen in the present study, may be used to separate
benign and malignant thyroid tissues provided appropriate
evidence-based data are taken into consideration [75]. Combining
small molecule inhibition of galectin-3 and doxorubicin treatment
of thyroid papillary cancer and cell lines increased drug response
and apoptosis [62]. In colonic cancers, nuclear localization of
galectin-3 is associated with resistance to 5-fluorouracil (5-FU)
treatment [76]. In the present study, colon cancers as a group had
low galectin-3 levels, though its contribution to progression is
unknown. In hepatocellular carcinomas, elevated serum or nuclear
galectin-3 indicated histologic grade and vascular invasion [77]; in
this study both galectin-3 and Beclin1 are elevated in liver cancer
when compared to normal tissues and possibly supports the
relative resistance to chemo-radiotherapy. As shown in other
studies, galectin-3 was highly expressed in the renal cancers [67].
High levels of galectin-3 in renal cell carcinomas was found in
primary and metastatic renal cell carcinomas; metastatic carcino-
mas had higher levels than primary carcinomas suggesting a role
in progression [78]. High galectin-3 levels in prostate cancers in
this study may support the findings in model animal studies. In the
prostate cancer cell line LNCaP that lacks galectin-3 (due to
promoter hypermethylation), induced expression of galectin-3
leads to reduced drug-induced apoptosis [71]. Similarly, over-
expression of galectin-3 in the prostate cancer cell line LNCaP that
lacks galectin-3 expression led to inhibition of tumor growth [79].
Galectin-3 may be cleaved by proteases during prostate cancer
progression, and PC3 prostate cancer cell line with reduced
galectin-3 showed reduced tumor growth in xenografts [80]. High
levels of galectin-3 in the prostate cancer samples could indicate,
low stage and less progressive disease [81,82].
Beclin1’s Input in Cancer Behavior
In contrast to the galectin-3 findings, Beclin1 was generally
down regulated in all tissue types and in many cancer subtypes. In
hepatocellular carcinomas, Beclin1 was increased compared to
normal and reduction in Beclin1 was reported as predictor of
disease free survival and aggressive cancers had low levels of
Beclin1 [83]; the findings in liver cancer could suggest less
aggressive cancers. Beclin1 was found to regulate estradiol activity
in breast cancer [84] and relatively normal levels found may
indicate estrogen activity. Beclin1 levels in prostate cancer may
support the findings in model animal studies. Several studies have
Figure 3. Box plots comparing galectin-3 and Beclin1 mRNA levels in all tissue types. (mean+/2standard deviation) Gal3=67.605e-02+/
21.3030 Beclin1=3.1806e-02+/26.4003e-02.
doi:10.1371/journal.pone.0026150.g003
Figure 4. Bar plot using the cancer/normal tissue ratios of
galectin-3 and Beclin1 expression from Tables 2 and 3.
Comparative changes in galectin-3 and Beclin1 expression in individual
cancer types are shown.
doi:10.1371/journal.pone.0026150.g004
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[85] and inhibition of mTOR ( target of rapamycin) induces
autophagy and increased response to irradiation [86]. Prostate
cancers had Beclin1 higher than normal suggesting possible
radiation response. There are no direct studies of changes in
Beclin1 in renal cancer, though small molecule inhibition of VHL
(von Hippel Landau) in cancer cells induced autophagy and
reduced growth [87]. In this study, renal cancers expressed Beclin1
below normal tissues and may suggest lack of activation of
autophagic cell death. In ovarian cancers, induction of autophagy
leads to tumor dormancy [88]. In this study, ovarian cancers had
Beclin1 levels below that in normal tissues indicating absence of
dormancy, and possibly aggressive behavior. Expression levels of
Beclin1 in ovarian, prostate and breast cancers may be influenced
by known deletions that occur in these cancers [36].
Galectin-3 and Beclin1 Together in Human Cancers
Deciphering the relevant cell death pathways in human cancer
may provide a way to select specific treatments to avoid unwanted
responses. Regulations of apoptosis and necroptosis do overlap but
are also unique to each cell death model [9,10]. Therefore,
suppression of galectin-3 and its pro-apoptosis functions will
promote necroptosis via RIP1 and RIP3 [11,14]. Proposed models
suggest that when autophagy is intact and functioning, cells will
undergo apoptosis when apoptosis pathway is preserved and go to
survival if apoptosis is deranged; on the other side, if autophagy is
defective but apoptosis is intact, cells will undergo apoptosis but
survive if apoptosis is deficient [89]. In human cancers with high
galectin-3 (presumed pro-apoptosis) and Beclin1, use of small
molecule inhibition of galectin-3 to enhance treatment response
may be beneficial. A recent study describes the use of siRNA and
GSC-100/MCP (modified pectin citrate) to inhibit galectin-3 in
prostate cancer cell of PC3 and enhance cisplatin treatment
response [90]. The present study and others suggest the relevance
of predetermining the presence of cell death pathway markers in
cancers to optimize use of combined drug and small molecule
inhibitors.
Study Limitations
The present study explored the use of qRT-PCR in determining
expression levels of two cancer cell death markers. Correlative
proteomics will benefit such studies to define correlating protein
content and or localization and provide additional support for
transcript levels. In prostate cancer and cell line LNCaP, promoter
methylation status affected tissue expression of galectin-3; hence
proteomics may need correlation with methylation status [91].
Survival and treatment responses are not part of the present study
as post-treatment follow-up and survival data were not available.
Correlating with survival and treatment response will be essential
components of larger samples and studies (normal and cancer
greater than 9 samples) aiming to define benefits of predefined
cancer cell death biomarkers for clinical use. Emerging methods of
next generation sequencing may need validation with enhanced
methods of qRT-PCR.
Utility of Kinetic/Regression Models for qRT-PCR
The present study also explores the use of Miner software (2.0)
for analysis of all quantitative polymerase-chain reaction data [50].
This and other methods reported by other investigators do not
require the use of standard curve and use linear or non-linear
regression modeling [51,52,53,54,92] and could enhance the
ability to conduct high-throughput quantitative real-time poly-
merase chain reaction(qRT-PCR) studies for corroborating, and
validating other microarray experiments.
Conclusions
The roles of galectin-3 and Beclin1 in apoptosis and autophagy
are well described. Galectin-3 and Beclin1 roles in cancer
progression and treatment response are supported by the
expression patterns in this study. The study used raw fluorescence
qRT-PCR data and Miner software (Miner 2.0) that uses logistic
regression model to calculate individual well efficiency and Ct
values. The method of qRT-PCR analysis lends itself to using
large numbers of tissue sets and may be useful in creating
biomarker sets based on gene networks that can be used for
diagnosis and predicting cancer treatment response.
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